MorphoSys investor relations material

Listen to the latest call from MorphoSys

MorphoSys AG is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases. It offers MOR101 for the treatment of acute lymphoblastic leukemia. The company was founded in 1992 and is headquartered in Planegg, Germany.

  • Ticker

  • Country


Dig deeper into the MorphoSys fundamentals on Quartr.